Small Stocks, Big Money™

Alta Global Group (NYSE American: MMA) launched its 20-week Warrior Training Program at UFC Gym locations in Costa Mesa and Huntington Beach, California, marking the start of a global rollout to over 150 gyms. This partnership is expected to generate over $7 million annually in potential gross revenue for Alta. Plans include expanding the program to 15 additional U.S. locations by mid-2025 and reaching international markets in the Middle East, UK, and beyond. UFC Gym will also leverage Alta’s mobile marketing platform, Hype, to boost member engagement across its extensive network.

bioAffinity Technologies, Inc. (Nasdaq: BIAF) appointed Dr. William Bauta as Chief Science Officer, succeeding Dr. Vivienne Rebel, who retired after leading the development of CyPath® Lung. Dr. Bauta, a seasoned innovator with a history at Genzyme and Ilex, has been with bioAffinity since 2016 and holds numerous patents, including key advancements in the company’s flagship diagnostic test for early-stage lung cancer. Under Dr. Bauta’s leadership, bioAffinity aims to accelerate the commercial rollout of CyPath® Lung, which boasts 92% sensitivity and 87% specificity, while expanding its pipeline of noninvasive diagnostics.

Soligenix (Nasdaq: SNGX) reported Q3 2024 financial results and recent operational highlights. Recent accomplishments include securing U.S. and European patents for synthetic hypericin production and partnering with Sterling Pharma Solutions to scale manufacturing. The company reported a net loss of $1.7 million for the quarter, with $9.8 million in cash as of September 30, 2024, positioning it to advance its pipeline while exploring strategic partnerships. Major upcoming milestones include plans to launch a confirmatory Phase 3 trial for HyBryte™ in cutaneous T-cell lymphoma (CTCL) and a Phase 2 study for SGX945 in Behçet's Disease by year-end. Top-line results from the Behçet's trial and ongoing SGX302 psoriasis study are expected in the first half of 2025.

ASP Isotopes Inc. (NASDAQ: ASPI) successfully closed its public offering of 2,754,250 shares of common stock, raising gross proceeds of $18.6 million. The offering included the full exercise of the underwriter's option to purchase an additional 359,250 shares at $6.75 per share. Canaccord Genuity acted as the sole bookrunner, with Cantor Fitzgerald as financial advisor. Funds will support ASP Isotopes’ mission to develop advanced materials and isotope enrichment technologies, including applications in healthcare, technology, and nuclear energy.